Adaptive Biotechnologies Corp at Morgan Stanley Global Healthcare Conference Transcript
Thanks, everyone, for joining us. My name is Tejas Savant, and I'm the Life Science Tools and Diagnostics Analyst at Morgan Stanley. On the stage with me are Chad Robins and Tycho Peterson, CEO and CFO of Adaptive. It's a pleasure to have you guys here.
Questions & Answers
Maybe, Chad, just to kick things off, big news this morning with the OrbiMed deal. Do you want to just spend a few minutes walking us through how the deal came about? What are the terms? And how do you see it sort of on a go-forward basis, transforming the opportunity for Adaptive?
Yes, sure. But first, Tejas, thanks for having us here. I really appreciate the opportunity -- we're really excited about the OrbiMed deal. And we've been talking about for the last couple of months that we were pursuing a non
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |